SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

BioMarin Signs Fabry Disease Treatment Development Deal

BioMarin signed an agreement with GC Biopharma and Hanmi to develop a treatment for Fabry disease.

BMRN
SquawkNews Desk 1 updates Updated Oct 29, 2026, 12:49 PM UTC

Story updates

12:49:55 PM UTC
SquawkNews
BIOMARIN PHARMACEUTICAL - TO MAKE $70 MLN UPFRONT PAYMENT; GC AND HANMI ELIGIBLE FOR MILESTONES AND

Related stories

Kvika to Host Q3 Results Presentation for Investors Kvika banki will host a presentation of its Q3 results for investors. M impact | EQUITY | Oct 29, 2026, 02:37 PM UTC Insmed shares gain 14.7% Insmed shares advanced 14.7%, according to the alert. M impact | EQUITY | Oct 29, 2026, 02:33 PM UTC US Stocks Fall; Nasdaq Drops More Than 1% Major US stock indexes fell, with the Nasdaq down more than 1%. Communication services was the weakest S&P 500 sector, while healthcare led. M impact | EQUITY | Oct 29, 2026, 02:33 PM UTC Nordecon Unit Signs €5.1M Contracts to Build Ukraine Warehouses Nordecon unit Eurocon Ukraine and Airlogix signed contracts to build three warehouses in Ukraine for UAH 259.5 million, approximately €5.1 million, excluding VAT. Work is expected L impact | EQUITY | Oct 29, 2026, 02:32 PM UTC Basler AG shares rise 10.4% after preliminary nine-month results Shares are on track for their best day since May, according to the alert. M impact | EQUITY | Oct 29, 2026, 02:32 PM UTC Rusal Agrees Bauxite, Alumina Joint Ventures in Ghana Russia's Rusal agreed to form bauxite and alumina joint ventures to tap a large deposit in Ghana. L impact | EQUITY | Oct 29, 2026, 02:32 PM UTC